TICKERNERD
Menu
SDGRSDGRHealthcare · Health Information Services

SDGR Stock Forecast: Schrödinger, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$20
+0.66% on the day

The 7 Wall Street analysts covering Schrödinger, Inc. hold a median 12-month price target of $20 — +1.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$1.5B
Ticker Nerd rank
53 / 100
Median analyst target
$20
Analysts covering
7
Total return, dividends reinvested
1W
+12.1%
1M
+30.5%
YTD
+10.2%
1Y
+0.7%
From 52W high
−12.5%
From 52W low
+78.0%
$11
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SDGR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Schrödinger, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Revisions
78
Issuance
71
Accruals
43
Momentum
41
Size
40
Volatility
37
Quality
30
Value
27

Growth (89): Sales and profits are climbing, and climbing faster than before.

Value (27): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SDGR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SDGR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26SDGRHigh $30Median $20Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $17Median $20High $30

The green dot is the last close — the median target sits +1.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026UBSAssumesNeutral$13 → $19
14 May 2026Morgan StanleyMaintainsEqual-Weight$19 → $17
14 May 2026Morgan StanleyMaintainsEqual-Weight—
8 Apr 2026KeybancMaintainsOverweight—
17 Mar 2026UBSMaintainsNeutral—
8 Jan 2026KeybancMaintainsOverweight—
8 Jan 2026TD CowenMaintainsBuy—
7 Jan 2026UBSInitiatesNeutral—
15 Dec 2025B of A SecuritiesUpgradeBuy—
8 Oct 2025KeybancMaintainsOverweight—
30 Sept 2025Goldman SachsInitiatesNeutral—
18 Aug 2025Morgan StanleyMaintainsEqual-Weight—
15 Aug 2025CitigroupDowngradeNeutral—
14 Aug 2025BarclaysInitiatesOverweight—
14 July 2025KeybancMaintainsOverweight—
16 Apr 2025KeybancMaintainsOverweight—
27 Feb 2025Piper SandlerMaintainsOverweight—
24 Jan 2025KeybancMaintainsOverweight—
13 Nov 2024BMO CapitalMaintainsOutperform—
17 Oct 2024BMO CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SDGR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SDGR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Schrödinger, Inc. (SDGR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
44.4×

Cheaper than 17% of US stocks

Price / sales
5.7×

Cheaper than 23% of US stocks

Price / book
4.4×

Cheaper than 25% of US stocks

EV / EBITDA
−7.9×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 45% of US stocks

Earnings growth (YoY)
7.5%

Higher than 45% of US stocks

Gross margin
55.1%

Higher than 68% of US stocks

Operating margin
−70.6%

Higher than 15% of US stocks

Net margin
−21.0%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−16.2%

Higher than 32% of US stocks

Return on assets
−14.4%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SDGR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
SDGRSchrödinger, Inc.$1.5B
53
OMDAOmada Health, Inc.$1.4B
85
OMCLOmnicell, Inc.$1.6B
98
CERTCertara, Inc.$1.3B
55
GDRXGoodRx Holdings, Inc.$1.2B
75
TDOCTeladoc Health, Inc.$1.1B
68
TALKTalkspace, Inc.$879.4M
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Schrödinger, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SDGR news & analysis

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Zacks Investment Research · 17 Aug 2026positive

Zacks Investment Research highlighted AI-powered drug discovery stocks including Schrödinger (SDGR), alongside RXRX, RLAY, and ABSI, noting they use AI platforms to transform drug discovery while advancing proprietary clinical pipelines.

Why it matters — The mention places Schrödinger among a group of AI-driven drug discovery companies, drawing attention to its AI-powered platform within the pharma sector as AI reshapes drug development.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 14 Aug 2026neutral

Schrödinger granted restricted stock units (RSUs) covering 3,315 shares of common stock to two newly hired employees on August 12, 2026, under its 2021 Inducement Equity Incentive Plan.

Why it matters — The grants serve as a material inducement for new hires, signaling the company's ongoing investment in talent through equity compensation.

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha has published the transcript of Schrödinger, Inc.'s Q2 2026 earnings call. The item consists of the earnings call transcript for the second quarter of fiscal 2026.

Why it matters — An SDGR watcher would care because the transcript offers management's own discussion of the company's most recent quarterly results.

Schrodinger Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

In its second-quarter earnings call, Schrodinger (NASDAQ: SDGR) reported accelerated annual contract value growth as demand broadened across large pharmaceutical companies, biotechnology firms, and materials-science customers. The company also launched early access for Bunsen, its agentic AI co-scientist.

Why it matters — SDGR watchers would care because the company highlighted accelerating contract value growth across diversified customer segments and introduced a new AI product, signaling commercial and product momentum.

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 6 Aug 2026positive

Schrodinger, Inc. reported Q2 quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.60 per share and improving from a loss of $0.59 per share a year ago.

Why it matters — SDGR watchers would note that the company exceeded analyst expectations and improved its earnings markedly compared to the prior-year period.

FAQ

Frequently asked questions about SDGR stock

What is the SDGR stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Schrödinger, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SDGR stock a buy right now?

Of the 7 analysts covering Schrödinger, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Schrödinger, Inc. 53 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SDGR?

As at 22 Aug 2026, Schrödinger, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will SDGR stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +1.5% from the last close, and Ticker Nerd's factor model ranks Schrödinger, Inc. 53 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SDGR stock forecast for 2030?

No analyst covering Schrödinger, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SDGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.

How has SDGR stock performed over the past year?

Schrödinger, Inc. returned +0.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Schrödinger, Inc. do?

Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications.

What is the latest news on SDGR?

The most recent item we track (Zacks Investment Research, 17 Aug 2026): "4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma". Zacks Investment Research highlighted AI-powered drug discovery stocks including Schrödinger (SDGR), alongside RXRX, RLAY, and ABSI, noting they use AI platforms to transform drug discovery while advancing proprietary clinical pipelines.

Company

About Schrödinger, Inc.

Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications. The company operates in two primary segments: Software and Drug Discovery. The Software segment provides advanced computational tools to biopharmaceutical and biotechnology companies, as well as materials science firms, transforming molecular discovery processes in life sciences and related industries. The Drug Discovery segment builds a portfolio of preclinical and clinical programs, advancing proprietary candidates like the MALT1 inhibitor SGR-1505 and pursuing collaborations with partners such as Novartis, Lilly, Ajax Therapeutics, and Copernic Catalysts to target specific therapeutic areas including oncology and rare diseases. Founded in 1990 and headquartered in New York, Schrödinger, Inc. plays a pivotal role in accelerating innovation at the intersection of computational chemistry, AI-driven simulations, and drug design, supporting research from target identification through clinical validation.

CEO Dr. Ramy Farid Ph.D. · 850 employees · United States · https://www.schrodinger.com